CN Patent

CN111187269A — 一种瑞德西韦中间体的合成方法

Assigned to ALPHA PHARMACEUTICAL Co Ltd JIANGSU PROVINCE · Expires 2020-05-22 · 6y expired

What this patent protects

本发明涉及医药中间体技术领域，尤其是一种瑞德西韦中间体的合成方法，其化学名称为(3R,4R,5R)‑2‑(4‑胺基吡咯[2,1‑f][1,2,4]三嗪‑7‑yl)‑3,4‑双(苄氧基)‑5‑((苄氧基)甲基)四氢呋喃‑2‑醇，具体为：先将吡咯并[2,1‑F][1,2,4]三嗪‑4‑胺用保护剂保护胺基，与二异丙基胺基锂反应，再加入2,3,5‑三苄氧基‑D‑核糖酸‑1,4‑内酯，最后脱保护基制得瑞德西韦中间体(3R,4R,5R)‑2‑(4‑胺基吡咯[2,1‑f][1,2,4]三嗪‑7‑yl)‑3,4‑双(苄氧基)‑5‑((苄氧基)甲基)四氢呋喃‑2‑醇。

USPTO Abstract

本发明涉及医药中间体技术领域，尤其是一种瑞德西韦中间体的合成方法，其化学名称为(3R,4R,5R)‑2‑(4‑胺基吡咯[2,1‑f][1,2,4]三嗪‑7‑yl)‑3,4‑双(苄氧基)‑5‑((苄氧基)甲基)四氢呋喃‑2‑醇，具体为：先将吡咯并[2,1‑F][1,2,4]三嗪‑4‑胺用保护剂保护胺基，与二异丙基胺基锂反应，再加入2,3,5‑三苄氧基‑D‑核糖酸‑1,4‑内酯，最后脱保护基制得瑞德西韦中间体(3R,4R,5R)‑2‑(4‑胺基吡咯[2,1‑f][1,2,4]三嗪‑7‑yl)‑3,4‑双(苄氧基)‑5‑((苄氧基)甲基)四氢呋喃‑2‑醇。

Drugs covered by this patent

Patent Metadata

Patent number
CN111187269A
Jurisdiction
CN
Classification
—
Expires
2020-05-22
Drug substance claim
No
Drug product claim
No
Assignee
ALPHA PHARMACEUTICAL Co Ltd JIANGSU PROVINCE
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.